FDA Approves Trastuzumab and Hyaluronidase-oysk for Breast Cancer
On February 28, the Food and Drug Administration approved trastuzumab and hyaluronidase-oysk injection for subcutaneous use (Herceptin Hylecta, Genentech Inc.) for the treatment of HER2-overexpressing breast cancer.
In Person Conference & ConventionJuly 18, 2026 at 3:30 PM CDT5005 Glumack Drive, Minneapolis, MN, USAInterContinental Hotel Minneapolis – St. Paul Airport, Minneapolis
